Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to 26.18%.

  • Neurocrine Biosciences' EBIT Margin rose 35600.0% to 26.18% in Q4 2025 from the same period last year, while for Dec 2025 it was 21.64%, marking a year-over-year decrease of 25800.0%. This contributed to the annual value of 21.64% for FY2025, which is 25800.0% down from last year.
  • Latest data reveals that Neurocrine Biosciences reported EBIT Margin of 26.18% as of Q4 2025, which was up 35600.0% from 30.07% recorded in Q3 2025.
  • Neurocrine Biosciences' EBIT Margin's 5-year high stood at 30.07% during Q3 2025, with a 5-year trough of 27.16% in Q1 2023.
  • Over the past 4 years, Neurocrine Biosciences' median EBIT Margin value was 21.74% (recorded in 2021), while the average stood at 18.29%.
  • Per our database at Business Quant, Neurocrine Biosciences' EBIT Margin skyrocketed by 464300bps in 2024 and then plummeted by -151500bps in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' EBIT Margin stood at 15.03% in 2021, then surged by 94bps to 29.17% in 2023, then decreased by -22bps to 22.62% in 2024, then increased by 16bps to 26.18% in 2025.
  • Its EBIT Margin was 26.18% in Q4 2025, compared to 30.07% in Q3 2025 and 21.18% in Q2 2025.